SAGE

Sage Therapeutics, Inc. (SAGE) Scenario Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Base Case

SAGE has a strong cash position and liquidity profile, with a current ratio of 9.16x and cash per share of 5.84.

The company still screens as unprofitable on a TTM basis, with negative operating margin (-2.66%) and negative free cash flow yield (-25.77%).

Valuation remains elevated on sales at 10.69x EV/Sales, which leaves limited margin for error despite the balance sheet strength.

Bull Case

A large cash balance and low leverage provide flexibility to fund development and absorb volatility.

Gross margin is extremely high at 98.69%, indicating strong underlying product economics if operating losses narrow.

If revenue scales and operating expenses normalize, the current liquidity cushion could support a rerating.

Bear Case

Persistent losses and negative cash generation remain the core downside risk, with ROE at -28.74% and ROIC at -31.78%.

High SG&A and R&D intensity continue to pressure profitability, with SG&A at 261.55% of revenue and R&D at 102.08% of revenue.

The stock could de-rate sharply if growth slows, since the valuation already assumes meaningful future improvement.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Sage Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →